GOSSAMER BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.668 USD | -0.30% |
|
-14.77% | -26.79% |
| Mar. 13 | Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM | |
| Mar. 12 | Gossamer Bio Announces Board of Directors Appointments | CI |
Chart calendar Gossamer Bio, Inc.
ae38c62dd5557f.7TbiFXra4ySHMC_EwMel9hMhDnoNX7cIax8BLL66n6w.v2mRdx2x1lbCYx2trZbmoSR3Iz05GtlQAWtgfcT40NmsRJN3TYu5bLYdfg~c04caa1cc090ea9d6aa2c370cbe1479d
Upcoming events on Gossamer Bio, Inc.
Past events on Gossamer Bio, Inc.
| 2024-03-05 07:31 am | Q4 2023 Earnings Release |
| 2024-02-07 03:00 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 2023-12-18 08:30 am | TORREY OLE Phase 2 Study Results Call |
| 2023-11-09 07:31 am | Q3 2023 Earnings Release |
| 2023-09-10 03:30 am | European Respiratory Society International Congress |
| 2023-08-08 04:01 pm | Q2 2023 Earnings Release |
| 2023-07-25 10:00 am | TORREY OLE and PROSERA Phase 2 Study Results Call |
| 2023-06-08 12:00 pm | Annual General Meeting |
| 2023-05-24 12:00 pm | American Thoracic Society International Conference - Poster No: 401 |
| 2023-05-22 09:04 am | American Thoracic Society International Conference |
| 2023-05-09 04:01 pm | Q1 2023 Earnings Release |
| 2023-05-02 03:00 pm | H.C. Wainwright BioConnect Investor Conference |
| 2023-03-17 07:31 am | Q4 2022 Earnings Release |
| 2023-03-15 03:05 pm | Barclays Global Healthcare Conference |
| 2022-12-06 08:00 am | TORREY Phase 2 study Results Call |
| 2022-11-07 | Society for Immunotherapy of Cancer Meeting - P855: Diacylglycerol Kinase Alpha and Zeta Dual Inhibi |
| 2022-11-03 04:01 pm | Q3 2022 Earnings Release |
| 2022-08-09 08:01 am | Interim 2022 Earnings Release |
| 2022-06-09 12:00 pm | Annual General Meeting |
| 2022-05-25 05:00 pm | UBS Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -185 -180 -2.76% | -233 -228 -2.15% | -214 -221 3.02% | -217 -218 0.75% | -182 -173 -4.99% | -171 |
|
EBIT Million USD | Released Forecast Spread | -186 -184 -1.11% | -234 -231 -1.31% | -216 -222 2.75% | -219 -219 0.33% | -184 -177 -3.87% | -172 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -180 -181 0.17% | -243 -237 -2.55% | -234 -235 0.3% | -229 -230 0.15% | -180 -176 -2.42% | -173 |
|
Net income Million USD | Released Forecast Spread | -180 -179 -0.62% | -243 -239 -1.73% | -234 -236 0.96% | -229 -231 0.57% | -180 -176 -2.33% | -180 |
|
EPS USD | Released Forecast Spread | -3,29 -3,13 -5.17% | -3,55 -3,50 -1.38% | -3,13 -3,14 0.37% | -2,71 -2,76 1.66% | -1,18 -1,21 2.63% | -0,74 |
| Announcement Date | 24/03/20 | 25/02/21 | 03/03/22 | 17/03/23 | 05/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -51,2 -54,3 5.69% | -53,9 -56,6 4.85% | -53,4 -54,5 2.04% | -55,6 -51,0 -8.93% | -53,9 -52,2 -3.26% | -47,5 -44,4 -6.93% | -45,8 -35,2 -30.11% | -40,1 -39,6 -1.27% | -48,7 -38,6 -26.26% | -35,2 | -36,3 | -36,4 | -37,5 | |
|
EBIT Million USD | Released Forecast Spread | -51,7 -56,7 8.82% | -54,3 -54,5 0.27% | -53,9 -51,6 -4.43% | -56,0 -52,3 -7.14% | -54,4 -54,9 1.03% | -47,9 -48,1 0.24% | -46,3 -45,5 -1.73% | -40,5 -47,1 14.09% | -49,0 -42,3 -15.91% | -41,3 | -42,3 | -43,3 | -44,9 | -46,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -56,3 -59,7 5.71% | -57,8 -58,3 0.89% | -56,5 -50,7 -11.42% | -59,4 -52,6 -12.83% | -55,8 -57,2 2.52% | -49,2 -49,9 1.56% | -42,5 -47,2 9.98% | -40,0 -48,7 17.81% | -48,1 -43,8 -9.91% | -41,3 | -42,7 | -43,8 | -45,6 | -50,1 |
|
Net income Million USD | Released Forecast Spread | -56,3 -59,3 5.11% | -57,8 -58,3 0.89% | -56,5 -53,2 -6.15% | -59,4 -54,0 -9.89% | -55,8 -57,6 3.24% | -49,2 -51,1 3.83% | -42,5 -47,9 11.37% | -40,0 -48,7 17.86% | -48,1 -44,1 -9.21% | -43,1 | -44,3 | -45,4 | -47,1 | -50,1 |
|
EPS USD | Released Forecast Spread | -0,74 -0,73 -1.37% | -0,76 -0,76 0.35% | -0,74 -0,70 -6.22% | -0,65 -0,64 -1.08% | -0,59 -0,62 4.27% | -0,52 -0,54 3.26% | -0,45 -0,49 8.88% | -0,21 -0,26 18.63% | -0,21 -0,21 1.01% | -0,19 | -0,19 | -0,19 | -0,19 | -0,21 |
| Announcement Date | 03/03/22 | 10/05/22 | 09/08/22 | 03/11/22 | 17/03/23 | 09/05/23 | 08/08/23 | 09/11/23 | 05/03/24 | - | - | - | - | - |
| Today 04:05 pm | QIAGEN N.V.: Q1 2024 Earnings Release |
| 2024-04-29 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-05-01 06:30 am | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 2024-05-01 06:30 am | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 2024-05-01 07:00 am | ALKERMES PLC: Q1 2024 Earnings Release |
| 2024-05-01 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Gossamer Bio, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- GOSS Stock
- Calendar Gossamer Bio, Inc.
